Neuroticism is an important risk factor for psychiatric traits, including depression 1 , anxiety 2, 3 , and schizophrenia [4] [5] [6] . At the time of analysis, previous genome-wide association ). We show that neuroticism's genetic signal partly originates in two genetically distinguishable subclusters 13 ('depressed affect' and 'worry'), suggesting distinct causal mechanisms for subtypes of individuals. Mendelian randomization analysis showed unidirectional and bidirectional effects between neuroticism and multiple psychiatric traits. These results enhance neurobiological understanding of neuroticism and provide specific leads for functional follow-up experiments.
, with weighting by sample size (Methods). We chose to perform meta-analysis on the available samples rather than use a two-stage discovery-replication strategy because Skol et al. 17 showed that this is almost always more powerful, even though less correction for multiple testing is required in the replication stage.
The quantile-quantile plot of the genome-wide meta-analysis on 449,484 subjects and 14,978,477 SNPs showed inflation (linkage disequilibrium score regression (LDSC) 18 : λ GC = 1.65, mean χ 2 statistic = 1.91; Fig. 1a and Supplementary Table 1 ), yet the LDSC intercept (1.02; standard error (s.e.) = 0.01) and ratio (2.1%) both indicated that the inflation was largely due to true polygenicity and the large sample size 19 . The λ GC value of 1.65 is consistent with values observed in recent large-sample GWAS (n > 100,000) for diverse and polygenic traits (Supplementary Note). The LDSC SNPbased heritability (h SNP 2 ) of neuroticism was 0.100 (s.e. = 0.003). The GWAS meta-analysis identified 9,745 genome-wide significant SNPs (P < 5 × 10 -8 ), of which 157 and 2,414 were located in known associated inversion regions on chromosomes 8 and 17 [10] [11] [12] , respectively ( Fig. 1b and Supplementary Fig. 3 ; see Supplementary  Table 2 for cohort-specific information). We used FUMA 20 , a tool to functionally map and annotate results from GWAS (Methods), and extracted 170 independent lead SNPs (158 new; see the Methods for definition of lead SNPs) that mapped to 136 independent genomic loci (124 new at the time of analysis) (Methods, Supplementary Tables 3-8, and Supplementary Note). Of all the lead SNPs, 4 were in exonic regions, 88 were in intronic regions, and 52 were in intergenic regions. Of the 17,794 SNPs in high linkage disequilibrium (LD) with one of the independent significant SNPs (see the Methods for definition), most were intronic (9,147; 51.4%) or intergenic (5,460; 30.7%), and 3.8% were annotated as potentially having a functional impact, with 0.9% (155 SNPs) being exonic ( Fig. 1c and Supplementary Table 9; see Supplementary Tables 10 and 11 for an overview of the chromatin state and regulatory functions of these SNPs). Of these 155 SNPs, 70 were exonic nonsynonymous (ExNS) ( Table 1 and Supplementary Table 12 ). The ExNS SNP with Letters Nature GeNetics the highest combined annotation-dependent depletion 21 (CADD) score (which indicates the likelihood of the SNP being deleterious; Methods) was rs17651549 (CADD score of 34), located on chromosome 17 in exon 6 of MAPT, with a GWAS P value of 1.11 × 10 −28 , in high LD with the lead SNP in that region (r 2 = 0.97). rs17651549 is a missense mutation (c.1108 C > T:p.Arg370Trp) that leads to an arginine-to-tryptophan change with allele frequencies matching the inversion in that region. The ancestral C allele is associated with a lower neuroticism score (see Table 1 and Supplementary Table 12 for a detailed overview of all functional variants in genomic risk loci).
Stratified LDSC 22 (Methods) showed significant enrichment for h 2 of SNPs located in conserved regions (enrichment = 13.79, P = 5.14 × 10 S u p e r -e n h a n c e r : 1 6 . 8 T r a n s c r i b e d : 3 4 . 5 I n t r o n : 3 8 . 7 ), and the lower dashed line shows the threshold for suggestive associations (P < 1 × 10
−5
). c, Pie charts showing the distribution of functional consequences of SNPs in LD with genome-wide significant lead SNPs in the meta-analysis, the minimum chromatin state across 127 tissue and cell types, and the distribution of RegulomeDB score (a categorical score between 1a and 7, indicating biological evidence of a SNP being a regulatory element, with a low score denoting a higher likelihood of a SNP being regulatory). d, Heritability enrichment of 22 functional SNP annotations calculated with stratified LD Score regression (summary statistics of the meta-analysis of neuroticism were used as input for this analysis). The circles signify the estimated enrichment, whereas the dashed line indicates enrichment of 1. Error bars represent 95% confidence intervals. TSS, transcription start site; CTCF, CCCTC binding factor; DGF, digital genomic footprint; TFBS, transcription factor binding site; DHS, DNase I hypersensitivity site. ), and trimethylated Lys4 on histone H3 (H3K4me3; enrichment = 2.14, P = 1.02 × 10 ) and acetylated Lys9 on histone H3 (H3K9ac; enrichment = 2.17, P = 3.06 × 10 −4 ) regions (Fig. 1d and Supplementary Table 13) .
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Polygenic scores (PGSs) calculated using PRSice 23 (clumping followed by P-value thresholding) and LDpred 24 in three randomly drawn hold-out samples (UKB only, n = 3,000 each; Methods) explained up to 4.2% (P = 1.39 × 10 −30 ) of the variance in neuroticism ( Supplementary Fig. 4 , Supplementary Table 14 , and Supplementary Note). Although the current sample size is considered to be large for GWAS and PGSs can be calculated with relatively low standard errors, the variance explained by all SNPs combined in the PGSs was still relatively small, although this was not unexpected given the h SNP 2 of 10%. Our current results thus have little predictive power in independent samples, mostly owing to the low average effect sizes of contributing SNPs, and indicate that the genetic architecture of neuroticism is extremely polygenic. We do note that our current meta-analysis did not include possible genetic interactions (as even with the current sample sizes power would be limited) but that adding these in the future may increase the predictive value of PGSs for neuroticism.
We used four strategies to link our SNP results to genes: positional, expression quantitative trait locus (eQTL), and chromatin interaction mapping (Methods) and genome-wide gene-based association study (GWGAS, using MAGMA 25 ). GWGAS evaluates the joint association effect of all SNPs within a gene to yield a genebased P value. Basesd on our meta-analysis results, 283 genes were implicated through positional mapping, 369 were implicated through eQTL mapping, and 119 were implicated through chromatin interaction mapping ( Fig. 2a and Nineteen of the 119 genes implicated through chromatin interaction mapping are especially notable, as they were implicated via interactions between two independent genome-wide significant genomic risk loci. There were several chromatin interactions in seven tissue types (aorta, hippocampus, left ventricle, right ventricle, liver, spleen, and pancreas) across two risk loci on chromosome 6 (Fig. 3a) . Two genes are present in locus 45 SNP P values and z scores were computed in METAL by a weighted z-score method (two-sided test). Per-SNP n values are reported in Supplementary Table 2 (for genome-wide significant SNPs) and in the publicly available summary statistics. rsID, rs number of the ExNS SNP; Exon, exon in which the SNP is located; Gene, nearest gene; A1, effect allele; MAF, minor allele frequency; GWAS P, SNP P value in the GWAS meta-analysis; z score, z score from the GWAS meta-analysis; r 2 , maximum r 2 of the SNP with one of the independent significant SNPs; Locus, index of the genomic risk locus; CADD, CADD score; RDB, RegulomeDB score; Minimum chromatin state, minimum chromatin state of the SNP. Results are reported on hg19 coordinates (GRCh37); NA, not available in RegulomeDB (alleles do not match). Genes containing multiple ExNS SNPs are annotated in bold. Table 15 ). This gene was also mapped by eQTLs in blood and transformed fibroblasts. Of the 19 genes mapped by two loci, 4 were located outside of the risk loci (HIST1H2AI, HIST1H3H, HIST1H2AK, and HIST1H4L) and 7 were also implicated by eQTLs in several tissue types (HFE in subcutaneous adipose, aorta, esophagus muscularis, lung, tibial nerve, sunexposed skin, and thyroid; HIST1H4J in blood and adrenal gland; and HIST1H4K, HIST1H2AK, HIST1H2BO, and XKR6 in blood).
We used the gene-based P values for gene set analysis in MAGMA 25 and tested 7,246 predefined gene sets derived from MSigDB 26 , gene expression profiles in 53 tissue types obtained from the GenotypeTissue Expression (GTEx) Project 27 , and 24 cell-type-specific expression profiles using RNA-seq information 28 (Methods). Neuroticism was significantly associated with genes predominantly expressed in six brain tissue types (Fig. 2d and Supplementary Tables 17 and 18 ) and with seven Gene Ontology (GO) gene sets, with the strongest association for neurogenesis (P = 4.43 × 10
) and neuron differentiation (P = 3.12 × 10 ; behavioral response to cocaine, P = 1.84 × 10 ) had largely independent associations, implying a role in neuroticism (Supplementary  Table 19 ). Conditional analyses of the tissue-specific expression ascertained general involvement of (frontal) cortex-expressed genes ( Supplementary Fig. 5 and Supplementary Table 20) .
Cell-type-specific gene set analysis showed significant association with genes expressed in multiple mouse-derived brain cell types (Fig. 2e , Methods, and Supplementary Table 21) , with dopaminergic neuroblasts (P = 3.49 × 10 −8 ), medium spiny neurons (P = 4.23 × 10 −8 ), and serotonergic neurons (P = 1.37 × 10 −7 ) showing the strongest associations. Conditional analysis indicated that these three cell types were also independently associated with neuroticism.
With the aim to further specify neuroticism's neurobiological interpretation, we compared the genetic signal of the full neuroticism trait to that of two genetically distinguishable neuroticism subclusters, 'depressed affect' and 'worry' (Methods), which we had previously established through hierarchical clustering of the genetic correlations between the 12 neuroticism items 13 . As a validation of the depressed affect dimension, we also compared the genetic signal of neuroticism and the two subclusters to that of depression. Genome-wide association analyses of the subclusters were conducted on the UKB data only (dictated by item-level data availability (Methods); depressed affect, n = 357,957; worry, n = 348,219). For depression, our meta-analysis comprised data from the UKB 14 (n = 362,696; Supplementary Fig. 6 ), 23andMe 15 (n = 307,354), and the Psychiatric Genetics Consortium (PGC 29 ; n = 18,759) (total n = 688,809, which is the largest n for depression thus far; r g between samples: 0.61-0.80; Methods and Supplementary  Table 22 ; see the Supplementary Note for details on the depression GWAS results). Genetic correlations of neuroticism with all three phenotypes were considerable (depression, r g = 0.79; depressed affect, r g = 0.88; worry, r g = 0.87; Supplementary Table 23 ). The positive genetic correlations between neuroticism and depression might in part be due to overlap in item content between the instruments used to gauge these phenotypes, reducing their operational distinctness 13 . The subclusters showed notable differences in genetic signal (for example, exclusive genome-wide significant associations on chromosomes 2 and 19 for depressed affect and on chromosomes 3 and 22 for worry; Supplementary Figs. 7-13 and Supplementary  Tables 24-26 ). Of the 136 genetic loci associated with neuroticism, 32 were also genome-wide significant for depressed affect (7 shared with depression) but not for worry, and 26 were also genome-wide significant for worry (3 shared with depression) but not for depressed affect ( Supplementary Fig. 13 and Supplementary Table 27 ). These results were mirrored by gene-based analyses ( Supplementary  Fig. 14, Supplementary Tables 28-30 , and Supplementary Note), suggesting that part of neuroticism's genetic signal originated specifically in one of the two subclusters, possibly implicating different causal genetic mechanisms. To further verify the biological distinctness of the two clusters, cluster-specific functional annotation was conducted, which demonstrated that, with respect to SNPs that were highly likely to have functional consequences (ExNS), the clusters were (i) distinct and (ii) adding information to the results of neuroticism sum-score analysis ( Supplementary Fig. 15 , Supplementary  Tables 31-34 , and Supplementary Note).
To test whether the signal of the gene sets implicated in neuroticism originated from one of the specific subclusters, we conducted conditional analyses, correcting neuroticism for depressed affect and worry scores separately ( Supplementary Fig. 16 and Supplementary Table 35 ). The association with axon part was markedly lower after correction for worry scores (uncorrected, P = 5.26 × 10 ; corrected for worry, P = 0.0013), suggesting that the involvement of axon part in neuroticism originates predominantly from the worry component.
To examine the genetic correlational pattern of neuroticism and to compare it to the patterns observed for depression, depressed affect, and worry, we used LDSC 18, 30 to calculate genetic correlations with 35 traits for which large-scale GWAS summary statistics were available (Methods and Supplementary 
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Bonferroni-corrected significant genetic correlations between neuroticism and other traits (α = 0.05/(4 × 35); P < 3.6 × 10 −4 ) ( Fig. 4 and Supplementary Table 37), which covered previously reported psychiatric traits (r g range: 0.20 to 0.82) and subjective well-being (r g = -0.68). These correlations were supported by enrichment of genes associated with neuroticism in sets of genes that had previously been implicated in psychiatric traits (Supplementary Table 38 ). The r g values of depression and depressed affect strongly mirrored each other (the correlation between their r g values was r = 0.98; Supplementary Note), which validated the depressed affect cluster. The correlational patterns for depressed affect and worry were markedly different (for example, anorexia nervosa, schizophrenia, and ever-smoker) and sometimes in opposite directions (for example, body mass index (BMI)). The genetic correlations of the full neuroticism trait seemed to be a mix of the genetic signal of both clusters, with neuroticism's r g values generally in between the cluster-specific r g values.
To investigate whether these genetic correlations reflected directional effects, we performed Mendelian randomization (MR) analysis using the GSMR package 31 (Methods). Among other things, we observed unidirectional effects of BMI on depression and depressed affect (b xy = 0.061, P = 4.96 × 10 −12 and b xy = 0.049, P = 5.35 × 10 −6 , respectively) and bidirectional associations between neuroticism and depression, as well as between all four main traits and subjective well-being, cognition, and several psychiatric disorders (Supplementary Table 39 and Supplementary Note).
We aimed to identify gene-drug interactions (using the Drug Gene Interaction database (DGIdb) 32, 33 ; Methods) of genes identified for each of the four traits, and we observed a large number of potential targets for pharmacotherapeutic intervention that were either shared between traits or distinct for each phenotype ( Supplementary Fig. 17, Supplementary Tables 40 and 41 , and Supplementary Note).
In conclusion, we identified 124 new genetic loci for neuroticism (73 taking into account a simultaneously conducted study by Luciano et al. 34 ; Supplementary Table 42 and Supplementary Note). Extensive functional annotations highlighted several genes implicated through multiple routes. We demonstrated the involvement of specific neuronal cell types and three independently associated genetic pathways, and we established the genetic multidimensionality of the neuroticism phenotype and its link with depression. The current study provides new leads and testable functional hypotheses for unraveling the neurobiology of neuroticism, its subtypes, and its genetically associated traits. 
URLs
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0151-7. Genetic correlations of neuroticism, depression, depressed affect, and worry with various traits and diseases (computed using cross-trait LD Score regression). LD Score regression (Methods) tested genome-wide SNP associations for the neuroticism score against previously published results for 35 neuropsychiatric outcomes, anthropometric and healthrelated traits, and brain morphology (Supplementary Tables 36 and 37 ). Genetic correlations among neuroticism, depression, depressed affect, and worry are displayed in the top part of the figure. Red and blue indicate positive and negative genetic correlations, respectively, whereas the hue indicates the strength of the genetic correlations. Sample sizes for the traits in this figure are presented in Supplementary Table 36. *P < 0.01; **Bonferroni-corrected P value threshold (P < 3.6 × 10
−4
).
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Methods
Samples. UK Biobank. The UKB study is a major data resource that contains genetic, as well as a wide range of phenotypic, data of ~500,000 participants aged 39-73 years at recruitment 14 . We used data released in July 2017, and selection (discussed below) resulted in final sample sizes of n = 372,903 and n = 362,696 individuals for neuroticism and depression, respectively (Supplementary Note). The UKB received ethical approval from the National Research Ethics Service Committee North West-Haydock (reference 11/NW/0382), and all study procedures were performed in accordance with the World Medical Association for medical research. The current study was conducted under UKB application 16406.
23andMe. 23andMe, Inc., is a large personal genomics company that provides genotype and health-related information to customers. For the neuroticism and depression meta-analyses, we used neuroticism and depression GWAS summary statistics, respectively, from a subset of 23andMe research participants (neuroticism, n = 59,206; depression, n = 307,354), which is described in more detail elsewhere 10, 35 . All included participants provided informed consent and were of European ancestry, and related individuals were excluded. Online data collection procedures were approved by the Ethical and Independent Review Services (E&I Review), an AAHRPP-accredited private institutional review board (see URLs).
Genetics of Personality Consortium. The GPC is a large collaboration concerning GWAS on personality. We used summary statistics of neuroticism from the first GPC personality meta-analysis (GPC1; see URLs) 9 on ten discovery cohorts (SardiNIA, NTR/NESDA, ERF, SAGE, HBCS, NAG, IRPG, QIMR, LBC1936, BLSA, and EGPUT), which included in total n = 17,375 participants of European descent. All included studies were approved by local ethics committees, and informed consent was obtained from all of the participants.
Psychiatric Genetics Consortium. The PGC unites investigators worldwide to conduct genetic meta-and mega-analyses for psychiatric disorders. We used summary statistics from the latest published PGC meta-analysis on depression (see URLs) 29 , which included data from eight cohorts (Bonn-Mannheim, GAIN, GenRED, GSK, MDD2000, MPIP, RADIANT, and STAR*D), which covered n = 18,759 participants of European descent. All included studies were approved by local ethics committees, and informed consent was obtained from all of the participants.
Phenotype assessment: neuroticism. UK Biobank. Neuroticism was measured with 12 dichotomous (yes or no) items of the Eysenck Personality Questionnaire Revised Short Form (EPQ-RS) 36 , using a touchscreen-based questionnaire at the UKB assessment centers (Supplementary Note). Participants with valid responses to < 10 items were excluded from analyses. A weighted neuroticism sum-score was calculated by adding up individual valid item responses and dividing that sum by the total number of valid responses. In addition, we constructed two scores based on subsets of genetically homogeneous neuroticism items, as established previously 13 through hierarchical clustering analysis of the genetic correlations between the 12 neuroticism items (Supplementary Note). Specifically, the sum of scores on four EPQ-RS items (i.e., "Do you often feel lonely?", "Do you ever feel 'just miserable' for no reason?", "Does your mood often go up and down?", and "Do you often feel 'fed up'?") was used to obtain scores for the cluster depressed affect. Similarly, the sum of scores on four other EPQ-RS items (i.e., "Are you a worried?", "Do you suffer from nerves?", "Would you call yourself a nervous person?", and "Would you call yourself tense or highly strung") was used to obtain scores for the cluster worry. In the item-cluster analyses, only participants with complete scores on all four items were included, which resulted in n = 357,957 and n = 348,219 for depressed affect and worry, respectively.
23andMe. Neuroticism was operationalized as the sum of eight neuroticism items (five-point Likert scale: from 'disagree strongly' to 'agree strongly') from the Big Five Inventory (BFI) 37, 38 , as obtained in an online survey. Only participants with valid responses to all items were included in the analyses (Supplementary Note).
Genetic Personality Consortium. All ten cohorts included in the first meta-analysis of the GPC used sums of the scores on 12 items (five-point Likert scale: from 'strongly disagree' to 'strongly agree') of the NEO-FFI 39 to measure neuroticism. If < 4 item scores were missing, data on invalid items were imputed by taking an individual's average score on valid items. Participants were excluded from analyses if they had invalid scores on > 3 items 9 (Supplementary Note).
Phenotype assessment: depression. UK Biobank. Depression was operationalized by adding up the scores on two continuous items ("Over the past two weeks, how often have you felt down, depressed or hopeless?" and "Over the past two weeks, how often have you had little interest or pleasure in doing things?"; both were evaluated on a four-point Likert scale: from 'not at all' to 'nearly every day'), resulting in a continuous depression score (as used previously 12 ). Only participants with scores on both items were included in the analyses, which resulted in n = 362,696 (Supplementary Note).
23andMe. This concerns a case-control sample. Four self-report survey items were used to determine case-control status. Cases were defined as replying affirmatively to at least one of these questions and not replying negatively to previous ones. Controls replied negatively to at least one of the questions and did not report being diagnosed with depression on previous ones (Supplementary Note).
Psychiatric Genetics Consortium. This concerns a case-control sample. Cases had a DSM-IV lifetime (sometimes (early-onset) recurrent) major depressive disorder (MDD) diagnosis, which was established through either structured diagnostic interviews or clinician-administered DSM-IV checklists. Most cases were ascertained from clinical sources, whereas controls were randomly selected from population resources and screened for a lifetime history of MDD 29 (Supplementary Note).
Genotyping and imputation. UK Biobank: neuroticism. We used genotype data released by the UKB in July 2017. The genotype data collection and processing are described in detail by the responsible UKB group 14 . In short, 489,212 individuals were genotyped on two customized SNP arrays (the UK BiLEVE Axiom array (n = 50,520) and the UK Biobank Axiom array (n = 438,692)), which covered 812,428 unique genetic markers (95% overlap in SNP content). After qualitycontrol procedures 14 , 488,377 individuals and 805,426 genotypes remained. Genotypes were phased and imputed by the coordinating team to approximately 96 million genotypes by using a combined reference panel, including the Haplotype Reference Consortium and the UK10K haplotype panel. Imputed and qualitycontrolled genotype data were available for 487,422 individuals and 92,693,895 genetic variants. As recommended by the UKB team, variants imputed from the UK10K reference panel were removed from the analyses due to technical errors in the imputation process.
In our analyses, only individuals of European descent (based on genetic principal components) were included. Therefore, principal components from the 1000 Genomes reference populations 40 were projected onto the called genotypes available in UKB. Subjects were identified as European if their projected principalcomponent score was closest (based on Mahalanobis distance) to the average score of the European 1000 Genomes sample 41 . European subjects with a Mahalanobis distance > 6 s.d. were excluded. In addition, participants were excluded based on withdrawn consent, UKB-provided relatedness (subjects with the most inferred relatives, third degree or closer, were removed until no related subjects were present), discordant sex, and sex aneuploidy. After selecting individuals based on available neuroticism sum-score and active consent for participation, 372,903 individuals remained for the analyses.
To correct for population stratification, 30 principal components were calculated on the subset of quality-controlled unrelated European subjects based on 145,432 independent (r 2 < 0.1) SNPs with MAF > 0.01 and INFO = 1 using FlashPC2 42 . Subsequently, imputed variants were converted to a hard call by using a certainty threshold of 0.9. Multiallelic SNPs, indels, and SNPs without unique rs identifiers were excluded, as well as SNPs with a low imputation scores (INFO score < 0.9), low MAF ( < 0.0001), and high missingness ( > 0.05). This resulted in a total of 10,847,151 SNPs that were used for downstream analysis.
UK Biobank: depression. A genotyping, imputation, and filtering procedure similar to the one described above for the UKB neuroticism GWAS was used for the UKB depression GWAS, which resulted in n = 362,696.
Genome-wide association analyses. UK Biobank: neuroticism. Genome-wide association analyses were performed in PLINK 43, 44 , using a linear regression model of additive allelic effects with age, sex, Townsend deprivation index, genotype array, and ten genetic European-based principal components as covariates (Supplementary Note).
UK Biobank: depression, depressed affect, and worry. The settings, covariates, and exclusion criteria for the UKB depression, UKB depressed affect, and UKB worry GWAS were the same as those described above for the UKB neuroticism GWAS, with 10,847,151 SNPs remaining after all exclusion steps (Supplementary Note).
Other samples. Summary statistics were used for 23andMe, GPC, and PGC. Details on the genome-wide association analyses of these samples can be found elsewhere (23andMe neuroticism Meta-analysis. To maximize the statistical power to detect associated genetic variants of small effect, we conducted meta-analyses for both neuroticism and depression 17 (Supplementary Note). All meta-analyses were performed in METAL 16 .
Neuroticism. The meta-analysis of the neuroticism GWAS in UKB, 23andMe, and GPC was performed on the P value of each SNP by using a two-sided sample-sizeweighted fixed-effects analysis. Bonferroni correction was applied to correct for multiple testing. The genetic signal correlated strongly between the three samples (r g range: 0.83 to 1.07; Supplementary Table 1) , supporting the decision to use meta-analysis.
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Depression. Because the UKB GWAS concerned a continuous operationalization of the depression phenotype, whereas 23andMe and PGC used case-control phenotypes, the odds ratios from the 23andMe and PGC summary statistics were converted to log odds, which reflected the direction of the effect. The meta-analysis was then performed on the P value of each SNP by using a two-sided sample-sizeweighted fixed-effects analysis. Bonferroni correction was applied to correct for multiple testing. Genetic correlations between the three samples were moderate to strong (r g range: 0.61 to 0.80; Supplementary Table 22) .
Genomic risk loci and functional annotation. Functional annotation was performed with FUMA 17 (see URLs), an online platform for functional mapping of genetic variants. We first defined independent significant SNPs, which had a genome-wide significant P value (5 × 10 −8
) and were independent at r 2 < 0.6. A subset of these independent significant SNPs, which were independent from each other at r 2 < 0.1, was marked as lead SNPs (based on LD information from UKB genotypes; see the Supplementary Note for a more detailed explanation). Subsequently, genomic risk loci were defined by merging lead SNPs that physically overlapped or for which LD blocks were less than 250 kb apart. Note that when analyzing multiple phenotypes, as in the current study, a locus may be discovered for different phenotypes while different lead SNPs are identified.
All SNPs in the meta-analysis results that were in LD (r 2 > 0.6) with one of the independent significant SNPs and that had P < 1.0 × 10 −5 and MAF > 0.0001 were selected for annotation. The rationale behind this inclusive approach was that the most significant SNP in the locus was not necessarily the causal SNP but that it might be in LD with the causal SNP. We thus annotated all SNPs in LD with the most significant SNP to get insight into the possible biological reasons for observing a statistical association. We note that liberalizing the r 2 and P-value thresholds can dilute the functional annotation results, whereas more stringent thresholds may result in exclusion of possibly interesting functional variants. Functional consequences for these SNPs were obtained by performing ANNOVAR 45 gene-based annotation using Ensembl genes. In addition, CADD scores (indicating the deleteriousness of a SNP, with scores > 12.37 seen as likely deleterious 21 ) and RegulomeDB scores 46 (for which a higher probability of having a regulatory function is indicated by a lower score) were annotated to SNPs by matching chromosome, position, reference, and alternative alleles. CADD scores integrate a number of diverse annotations into a single measure that correlates with pathogenicity, disease severity, and experimentally measured regulatory effects and complex trait associations 21 .
Gene mapping. SNPs in genomic risk loci that were genome-wide significant or were in LD (r 2 > 0.6) with one of the independent significant SNPs were mapped to genes in FUMA 20 using one of three strategies. First, positional mapping uses the physical distances (i.e., within 10-kb windows) from known protein-coding genes in the human reference assembly (GRCh37 or hg19) to map SNPs to genes. The second strategy, eQTL mapping, uses information from three data repositories (GTEx, Blood eQTL browser, and BIOS QTL browser) and maps SNPs to genes based on a significant eQTL association (i.e., where the expression of the gene is associated with allelic variation at the SNP). eQTL mapping is based on cis-eQTLs, which can map SNPs to genes up to 1 Mb away. FUMA applied a false discovery rate (FDR) of 0.05 to define significant eQTL associations. Third, chromatin interaction mapping mapped SNPs to genes based on a significant chromatin interaction between a genomic region in a risk locus and promoter regions of genes (250 bp upstream and 500 bp downstream of a TSS). This type of mapping does not have a distance boundary (as in eQTL mapping) and may therefore involve long-range interactions. Currently, FUMA contains Hi-C data for 14 tissue types from the study of Schmitt et al. 47 . Notably, as chromatin interactions are usually defined in a certain resolution (in the current study, 40 kb), an interacting region may span several genes. Hence, this method would map all SNPs within these regions to genes in the corresponding interaction region. By integrating predicted enhancers and promoters in 111 tissue and cell types from the Roadmap Epigenomics Project 48 , we aimed to prioritize candidate genes from chromatin interaction mapping. Using this information, FUMA selected chromatin interactions for which one region involved in the interaction overlapped with predicted enhancers and the other overlapped with predicted promoters 250 bp upstream and 500 bp downstream of the TSS of a gene. Similar to eQTL mapping, we used an FDR of 1 × 10 −5 to define significant interactions.
Gene-based analysis. GWGAS can identify genes in which multiple SNPs show moderate association to the phenotype of interest without reaching the stringent genome-wide significance level. At the same time, because GWGAS takes all SNPs within a gene into account, a gene harboring a genome-wide significant SNP may not be implicated by GWGAS analyses when multiple other SNPs within that gene show only very weak association signal. The P values from the SNP-based GWAS meta-analyses for neuroticism and depression, and the GWAS for depressed affect and worry, were used as input for the GWGAS in MAGMA (see URLs) 25 , and all 19,427 protein-coding genes from the NCBI 37.3 gene definitions were used. We annotated all of the SNPs in our genome-wide association (meta-)analyses to these genes, resulting in 18,187, 18,187, 18,182, and 18,182 genes that were represented by at least one SNP in the neuroticism meta-analysis, the depression meta-analysis, the depressed affect GWAS, and the worry GWAS, respectively. We included a window around each gene of 2 kb before the TSS and 1 kb after the transcription stop site. Gene association tests were performed, taking into account the LD between SNPs, and a stringent Bonferroni correction was applied to correct for multiple testing (0.05/number of genes tested: P < 2.75 × 10
−6
Gene set analysis. We used MAGMA 25 to test for association of predefined gene sets with neuroticism, depression, depressed affect, and worry. A total of 7,246 gene sets were derived from several resources, including BioCarta, KEGG, Reactome 49 , and GO. All gene sets were obtained from MSigDB version 6.0 (see URLs). Additionally, we performed gene set analysis on 53 tissue expression profiles obtained from the GTEx portal (see URLs) and on 24 cell-type-specific expression profiles.
For all gene sets, we computed competitive P values, which result from testing whether the combined effect of genes in a gene set is significantly larger than the combined effect of the same number of randomly selected genes (in contrast to testing against the null hypothesis of no effect; self-contained test). Here we only report Bonferroni-corrected (α = 0.05/7,323 = 6.83 × 10 −6 ) competitive P values, which were more conservative than the self-contained P values.
Cell-type-specific expression analysis. Definition and calculation of gene sets for cell-type-specific expression is described in detail elsewhere 28, 50 . Briefly, brain-celltype expression data were drawn from single-cell RNA-seq (scRNA-seq) data from mouse brain 28 . For each gene, the value for each cell type was calculated by dividing the mean unique molecular identifier (UMI) counts for the given cell type by the summed mean UMI counts across all cell types 28 . MAGMA 25 was used to calculate associations between gene-wise P values from the meta-analysis and cell-typespecific gene expression. Genes were grouped into 40 equally sized bins by specificity of expression, and bin membership was subsequently regressed on gene-wise association with neuroticism in the meta-analysis. Results were deemed significant if the association P values were smaller than the relevant Bonferroni threshold.
Conditional gene set and tissue expression analyses. Conditional gene set analyses were performed using MAGMA 25 to determine which tissue expression levels and MSigDB gene sets represented independent associations. In these regression-based analyses, the effect of a gene set (or tissue expression) of interest was conditioned on the effects of another gene set (or tissue expression) to correct the association of the tested gene set for any effect it shared with the conditionedon gene set.
For the MSigDB gene sets, we conducted two series of conditional analyses. First, we performed forward selection on the initially significant gene sets, in each step selecting the most strongly associated gene set after conditioning on all already-selected gene sets (Supplementary Table 19 ). Second, to test whether the association of gene sets to neuroticism was primarily driven by the association signal of one specific subcluster, we also re-ran the GO gene set analyses, conditioning on the gene z scores of depressed affect or worry (Supplementary  Table 35 ). If the gene set association decreased after conditioning on one cluster but did not decrease or did so to a lesser extent when conditioned on the other, then this suggested that neuroticism's association to that gene set was primarily driven by the genetic effects of the first, and not the second, item cluster.
Genetic correlations.
Genetic correlation (r g ) values were computed using LD Score regression 18, 30 (see URLs). The significance of the genetic correlations of neuroticism, depression, depressed affect, and worry with 35 behavioral, social, and (mental) health phenotypes for which summary statistics were available was determined by correcting for multiple testing through a stringent Bonferronicorrected threshold of P < 0.05/(4 × 35) = 3.6 × 10 
Mendelian randomization.
We performed MR analysis to test whether genetic correlations could be explained by directional effects between traits. Generalized summary-data-based MR (GSMR) 31 , a summary-statistics-based MR method that uses independent genome-wide significant variants as instrumental variables, was used for MR analysis. Causal associations were tested between the 4 traits and the 21 traits that showed significant genetic correlations (r g values) in LD Score regression analysis with at least one of the 4 traits. To test for unidirectional and bidirectional effects, we performed both forward and reverse GSMR analyses (i.e., using the four GWAS traits either as predictor or as outcome). Associations were Bonferroni corrected for multiple testing with P < 0.05/(21 × 4 × 2) = 2.98 × 10 . Partitioned heritability. To investigate the relative contribution to the overall SNP-based heritability annotated to 22 specific genomic categories, we partitioned SNP heritability by binary annotations using stratified LD Score regression 22 . Information about binary SNP annotations was obtained from the LD Score website (see URLs). Enrichment results reflected the X-fold increase in h 2 proportional to the number of SNPs (for example, enrichment = 13.79 for SNPs in conserved regions implies that a 13.79-fold increase in h 2 is carried by SNPs in these region, corrected for the proportion of SNPs in these regions compared to all tested SNPs).
Letters
Nature GeNetics
Gene drug targets. We aimed to identify potential druggable targets by searching for the implicated genes (by one of the gene-mapping strategies) in DGIdb 32, 33 (version 3.0; see URLs). The DGIdb contains mined data from several resources and provides a comprehensive overview of the druggability of gene targets. First, we searched 20 drug-gene databases for interactions with existing medicines based on 48 known interaction types with genes that were implicated in each of the four phenotypes. Filtering was performed based on known interaction types and interactions with US Food and Drug Administration (FDA)-approved pharmaceutical compounds. Second, to identify genes that may form targets for novel therapies in addition to existing medicines, we searched for the potential gene druggability of gene targets and performed an additional search in ten DGIdb databases containing information about gene targetability.
Polygenic risk scoring. To test the predictive accuracy (Δ R
2 ) of our meta-analysis results for neuroticism, we calculated a PGS based on the SNP effect sizes of the current analysis. For independent samples, we used three hold-out samples; we removed 3,000 individuals from the discovery sample (UKB only, as we had access only to individual-level data from this sample) and re-ran the genomewide analyses. We repeated this three times, to create three randomly drawn, independent hold-out samples. Next, we calculated a PGS on the individuals in each of the three hold-out samples. PGSs were calculated using LDpred 24 and PRSice 23 (clumping followed by P-value thresholding). For LDpred, PGSs were calculated based on different LDpred priors (P LDpred = 0.01, 0.05, 0.1, 0.5, 1, and infinitesimal). The explained variance (R 2 ) was derived from the linear model, using the neuroticism summary score as the outcome, while correcting for age, sex, array, Townsend deprivation index, and genetic principal components.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability.
Our policy is to make genome-wide summary statistics (sumstats) publicly available. Sumstats from our neuroticism meta-analysis, our depression meta-analysis, and the genome-wide association analyses for depressed affect and worry are available for download at the website of the Department of Complex Trait Genetics, CNCR (see URLs).
Note that our freely available meta-analysis sumstats concern results excluding the 23andMe sample. This is a non-negotiable clause in the 23andMe data transfer agreement, which is intended to protect the privacy of the 23andMe research participants. To fully recreate our meta-analysis results for neuroticism (i) obtain the sumstats from Lo et al. (2017) for 23andMe (see below) and (ii) conduct a meta-analysis of our sumstats with those from Lo et al. To fully recreate our meta-analysis results for depression (i) obtain the sumstats from Hyde et al. 35 for 23andMe (see below) and (ii) conduct a meta-analysis of our sumstats with those for Hyde et al. 35 . 23andMe participant data are shared according to community standards that have been developed to protect against breaches of privacy. Currently, these standards allow for the sharing of summary statistics for at most 10,000 SNPs. The full set of summary statistics can be made available to qualified investigators who enter into an agreement with 23andMe that protects participant confidentiality. Interested investigators should contact David Hinds (dhinds@23andme.com) for more information.
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For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined. We made use of data collected by external sources (UK biobank, 23andMe, Genetics of Personality Consortium and the Psychiatric genetics Consortium). For all samples the sample size consists of all individuals that remain after quality control of the data and exclusion of withdrawn subjects. Detailed information on the samples used, as well as the exclusion/inclusion criteria, are provided in the Online Methods (sections: Samples, Genotyping and imputation, Genome-wide association analyses).
Data exclusions
Describe any data exclusions. See Online Methods. For UKB data: we excluded participants from further analyses if they had excessive missing phenotypic data (section: Phenotype assessment), did not pass standard quality control or withdrew their consent to participate in the UK biobank study (section: Genotyping and imputation).
Replication
Describe whether the experimental findings were reliably reproduced.
We used a meta-analytic approach, which inherently evaluates the combined evidence for significant association across samples. In addition, we used polygenic risk score profiling to determine whether our current results were predictive of the same outcome in three independent samples.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
NA
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
NA
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Standard statistical genetics software packages were used for the analyses described in the current manuscript (all are described in more detail in the Online Methods). Below we list the software used: Plink -Open-source software (Purcell et For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
